British Pharmacological Society--summer meeting.
The summer meeting of the British Pharmacological Society meeting covered many aspects of modern pharmacology, with a therapeutic slant reflecting the association with the German Society of Experimental and Clinical Pharmacology and Toxicology. At the meeting, Knoll Pharmaceuticals, which has close ties with Nottingham, the venue for the conference, disclosed detailed information relating to two novel compounds currently being developed for the treatment of psychosis. Further encouraging noises were expounded from two companies regarding the FLIPR system for high throughput screening of G-protein coupled receptors. Interesting information relating to expression profiles of voltage-dependent sodium channels and 5-HT(6) receptors. The therapeutic potential of targeting GABA(B) receptors in treating epilepsy and the link between anandamide and vanilloid receptors were two other issues addressed. Finally, a cautionary tale was reported for those expressing 5-HT receptors in cell lines.